Gregg Gilbert
Stock Analyst at Truist Securities
(2.29)
# 2,621
Out of 4,944 analysts
84
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $11.34 | +49.91% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $37.86 | -2.27% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $47.85 | +75.55% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $660.49 | -20.51% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $6.51 | +99.69% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $11.62 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $82.71 | +12.44% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $15.63 | +207.10% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.00 | +2,502.60% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $1.56 | +9,515.38% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $23.66 | +229.67% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $152.44 | -48.83% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $17.21 | +4.59% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $117.12 | +49.42% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $201.47 | -67.24% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $11.34
Upside: +49.91%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $37.86
Upside: -2.27%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $47.85
Upside: +75.55%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $660.49
Upside: -20.51%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $6.51
Upside: +99.69%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $11.62
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $82.71
Upside: +12.44%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $15.63
Upside: +207.10%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.00
Upside: +2,502.60%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $1.56
Upside: +9,515.38%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $23.66
Upside: +229.67%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $152.44
Upside: -48.83%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $17.21
Upside: +4.59%
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $117.12
Upside: +49.42%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $201.47
Upside: -67.24%